COMPANY UPDATES
13
Jun
2018
Novoheart Wins Coveted 2018 MedTech Breakthrough Award

Novoheart announced today that its MyHeartTM platform, including the world’s first and only ‘human heart-in-a-jar’, has been selected as 2018’s “Best New Technology Solution – Drug Development” by MedTech Breakthrough, an independent organization that recognizes the top companies, technologies and products in the global health and medical technology market.

06
Jun
2018
Novoheart Receives C$400,000 in Research Funding from the Innovation and Technology Commission of Hong Kong

Novoheart Limited, a wholly owned subsidiary of global stem cell biotechnology company, Novoheart Holdings Inc., has been awarded a non-dilutional government grant of C$400,000 from the Innovation and Technology Commission (ITC) of Hong Kong. The grant has been awarded to Novoheart to further enhance the drug screening capabilities of its proprietary human ventricular cardiac tissue strip, as part of its unique MyHeartTM Platform of bioengineered human heart tissues. Including this latest grant, Novoheart has received close to C$2.2 million R&D funding from the ITC.

31
May
2018
Novoheart Becomes Member of International Consortium Advancing Cardiac Safety in Drug Development

Novoheart announced today that it has become a member of the Cardiac Safety Technical Committee of the Health and Environmental Sciences Institute (HESI), an industry-led, international consortium including major pharmaceutical and biotechnology companies that aims to advance innovative approaches for early detection, prediction, and elimination of cardiac risk in drug development.

11
May
2018
Novoheart Holdings Inc. Reports Third Quarter 2018 Financial Results

Novoheart Holdings Inc. reports financial results for the three and nine months ended March 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS).